These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 18533761)
1. Side effects as influencers of treatment outcome. Sharif Z J Clin Psychiatry; 2008; 69 Suppl 3():38-43. PubMed ID: 18533761 [TBL] [Abstract][Full Text] [Related]
2. Medical risk in patients with bipolar disorder and schizophrenia. Newcomer JW J Clin Psychiatry; 2006; 67 Suppl 9():25-30; discussion 36-42. PubMed ID: 16965186 [TBL] [Abstract][Full Text] [Related]
3. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. McIntyre RS; Konarski JZ J Clin Psychiatry; 2005; 66 Suppl 3():28-36. PubMed ID: 15762832 [TBL] [Abstract][Full Text] [Related]
4. Medical risk in patients with bipolar disorder and schizophrenia. Newcomer JW J Clin Psychiatry; 2006 Nov; 67(11):e16. PubMed ID: 17201046 [TBL] [Abstract][Full Text] [Related]
5. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. Newcomer JW J Clin Psychiatry; 2009; 70 Suppl 3():30-6. PubMed ID: 19570499 [TBL] [Abstract][Full Text] [Related]
6. Treatment of bipolar disorders and metabolic syndrome: implications for primary care. Bell PF; McKenna JP; Roscoe BM Postgrad Med; 2009 Sep; 121(5):140-4. PubMed ID: 19820282 [TBL] [Abstract][Full Text] [Related]
7. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Tirupati S; Chua LE Aust N Z J Psychiatry; 2007 Jul; 41(7):606-10. PubMed ID: 17558623 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. Kilbourne AM; Post EP; Bauer MS; Zeber JE; Copeland LA; Good CB; Pincus HA J Affect Disord; 2007 Sep; 102(1-3):145-51. PubMed ID: 17276514 [TBL] [Abstract][Full Text] [Related]
9. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions. Megna JL; Schwartz TL; Siddiqui UA; Herrera Rojas M Ann Clin Psychiatry; 2011 May; 23(2):131-40. PubMed ID: 21547274 [TBL] [Abstract][Full Text] [Related]
15. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]. Bret P; Bret MC; Queuille E Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381 [TBL] [Abstract][Full Text] [Related]
16. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects. Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288 [TBL] [Abstract][Full Text] [Related]
17. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. Correll CU J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. van Winkel R; De Hert M; Van Eyck D; Hanssens L; Wampers M; Scheen A; Peuskens J Bipolar Disord; 2008 Mar; 10(2):342-8. PubMed ID: 18271914 [TBL] [Abstract][Full Text] [Related]
19. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Elmslie JL; Porter RJ; Joyce PR; Hunt PJ; Shand BI; Scott RS Aust N Z J Psychiatry; 2009 Jan; 43(1):53-60. PubMed ID: 19085528 [TBL] [Abstract][Full Text] [Related]
20. Use of antipsychotics in children and adolescents. Findling RL; Steiner H; Weller EB J Clin Psychiatry; 2005; 66 Suppl 7():29-40. PubMed ID: 16124839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]